Quote:

---

Can’t Wait to see what the impacts were on inflammatory biomarkers like CRP.

---

We didn't lower CRP in any significant manner in the phase 2 trial. Dr. Yang also didn't see a drop when he used it for Covid.

I posited that blood levels of CRP didn't change because CRP uses intracellular calcium to join into a pentagonal shape. That pentagonal shape is necessary for it to bind to its receptors and activate. Leronlimab lowers intracellular calcium meaning that instead of pentagonally assembling it remains unassembled in the bloodstream and doesn't lower. But because it can't bind it doesn't activate downstream inflammatory factors. So CRP would not be a good marker for inflammation when leronlimab is used. It certainly explains why EN-RAGE (another inflammation marker) dropped but CRP didn't.

Hopefully in the HIV inflammation trial or some other trial they not only measure bloodstream CRP but also the amount of bound CRP. That should sort out why CRP isn't being lowered.